Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance

European Journal of Endocrinology

Volumn 137, Issue 2, 1997, Pages 127-131

  Ahrén, Bo ^a,c   Larsson, Hillevi ^a   Holst, Jens J ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; FASTING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE; REFERENCE VALUES;

EID: 0030845083     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1370127     Document Type: Article

References (38)

1. McIntyre N, Holdsworth D & Turner DS. New interpretation of oral glucose tolerance. Lancet 1964 ii 20-21.
2. Creutzfeldt W. The incretin concept today. Diabetologia 1979 16 75-85.
3. Fehmann HC, Göke R & Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocrine Reviews 1995 16 390-410.
4. Kreymann B, Williams G, Ghatei MA & Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 ii 1300-1304.
5. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insulinar axis. Diabetologia 1992 35 701-711.
6. Fehmann HC, Göke B, Göke R, Trautmann ME & Arnold R. Synergistic stimulatory effect of glucagon-like-peptide-1 (7-36)amide and glucose-dependent insulin-releasing polypeptide on the endocrine pancreas. FEBS Letters 1989 252 109-112.
7. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM & Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. New England Journal of Medicine 1988 319 1500-1506.
8. King H, Zimmet P, Raper LR & Balkau B. The natural history of impaired glucose tolerance in the Micronesian population of Nauru: a six-year follow-up study. Diabetologia 1984 26 39-43.
9. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, Takaku F & Kosaka K. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984 26 44-49.
10. Keen H, Jarrett RJ & McCartney P. The ten-year follow-up of the Bedford survey 1962-1972: glucose tolerance and diabetes. Diabetologia 1982 22 73-78.
11. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J & Gerich J. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. New England Journal of Medicine 1992 326 22-29.
12. Larsson H, Berglund G & Ahrén B. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. Journal of Clinical Endocrinology and Metabolism 1995 321 337-343.
13. Larsson H & Ahrén B. Islet dysfunction in obese women with impaired glucose tolerance. Metabolism 1996 45 502-509.
14. Larsson H & Ahrén B. Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 1996 39 1099-1107.
15. Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M, Yamatani K, Tominaga M & Sasaki H. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetologia 1995 32 165-169.
16. Groop PH. The influence of body weight, age and glucose tolerance on the relationship betwen GIP secretion and beta-cell function in man. Scandinavian Journal of Clinical and Laboratory Investigation 1989 49 367-379.
17. Creutzfeldt W, Ebert R, Nauck M & Stöckmann F. Disturbances of the entero-insulin axis. Scandinavian Journal of Gastroenterology 1983 83 (Suppl) 111-119.
18. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R & Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. Journal of Clinical Investigation 1993 91 301-307.
19. Ørskov C, Jeppesen J, Madsbad S & Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. Journal of Clinical Investigation 1991 87 415-423.
20. Hutson WR, Roehrkasse RL & Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 1989 96 11-17.
21. Parkman HP, Harris AD, Miller MA & Fisher RS. Influence of age, gender, and menstrual cycle on the normal electrogastrogram. American Journal of Gastroenterology 1996 91 127-132.
22. Stanghellini V, Tosetti C, Paternico A, Barbara G, Morselli-Labate AM, Monetti N, Marengo M & Corinaldesi R. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996 110 1036-1042.
23. Larsson H, Ahrén B, Lindgärde F & Berglund G. Fasting blood glucose in determining prevalence of diabetes in a large, homogenous population of Caucasian middle-aged women. Journal of Internal Medicine 1995 237 537-541.
24. World Health Organisation. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series no. 727. Geneva, Switzerland: World Health Organisation, 1985.
25. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ & Sestoft L. Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. Journal of Clinical Endocrinology and Metabolism 1983 56 1306-1312.
26. Krarup T & Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides 1984 9 335-346.
27. Kuzio M, Dryburgh JR, Malloy KM & Brown JC. Radioimmunoassay for gastric inhibitory polypeptide. Gastroenterology 1974 66 357-364.
28. Ørskov C, Rabenhöj L, Kofod H, Wettergren A & Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994 43 535-539.
29. Norusis MJ. SPSS for Windows: Base System User's Guide, Release 5.0. Chicago, IL: SPSS, 1992.
30. Heinze E, Schlickenrieder J, Holl RW & Ebert R. Reduced secretion of gastric inhibitory polypeptide in Turner patients with impaired glucose tolerance. European Journal of Pediatrics 1991 150 339-342.
31. Kruszynska YT, Ghatei MA, Bloom SR & McIntyre N. Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 (7-36 amide) after oral glucose in cirrhosis. Hepatology 1995 21 933-941.
32. Hinds A, Sheehan AG, Machida H & Parsons HG. Postprandial hyperglycemia and pancreatic function in cystic fibrosis patients. Diabetes Research 1991 18 69-78.
33. Schirra J, Katschinsky M, Weidmann C, Schäfer T, Wank U, Arnold G & Göke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. Journal of Clinical Investigation 1996 97 92-103.
34. Ebert R & Creutzfeldt W. Decreased GIP through impairment of absorption. Frontiers in Hormone Research 1980 7 192-201.
35. Sykes S, Morgan LM, English J & Marks V. Evidence for preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues. Journal of Endocrinology 1980 85 201-207.
36. Bryer Ash M, Cheung A & Pederson RA. Feedback regulation of glucose-dependent insulinotropic polypeptide (GIP) secretion by insulin in conscious rats. Regulatory Peptides 1994 5 101-109.
37. Hermann C, Göke R, Richter G, Fehmann HC, Arnold R & Göke B. Glucagon-like peptide 1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995 56 117-126.
38. Roberge JN & Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993 133 233-240.